Jun 4, 2020
June 4, 2020, Baltimore, Md. – KaloCyte, Inc., a preclinical-stage healthcare biotechnology company developing a synthetic, bio-inspired red blood cell substitute for use in settings when stored red blood cells are not available, is one of just 10 life science...
May 5, 2020
May 5, 2020, Baltimore, Md. – KaloCyte, Inc., a preclinical-stage healthcare biotechnology company developing a synthetic, bio-inspired red blood cell substitute for use in settings when stored red blood cells are not available, announced today that the National...
Apr 2, 2020
Blood can be a scarce resource, but a multitude of approaches are promising new ways to store, create, and deliver blood’s component parts to patients in need. Click here to read the article in its entirety. Author, Leah Shaffer, science writer, for Proceedings of the...
Mar 24, 2020
Nivesh Mittal, PhD, Product Development Scientist, to propel production of ErythroMer™ March 24, 2020, Baltimore, Md. – KaloCyte, Inc., a preclinical-stage healthcare biotechnology company developing ErythroMer, a synthetic, bio-inspired red blood cell...
Mar 17, 2020
As KaloCyte has re-established itself in Maryland, Elaine E. Haynes, President and CEO, said they are moving closer to bringing their artificial blood cell product, ErythroMer, to clinical trials and are eyeing a Series A funding round later this year. Read the...
Nov 7, 2019
The Capital M Podcast #LifeScienceRevolution: Proximity to Resources with KaloCyte. Listen to part 3 of the Capital M podcast, #LifeScienceRevolution: Proximity to Resources with KaloCyte. In this episode, Marty discusses business in Maryland with Elaine E. Hayne,...
